85 related articles for article (PubMed ID: 28044937)
1. Cytokine Status of Serum in Ovarian Cancer Patients with Different Tumor Neoadjuvant Chemotherapy Response.
Antoneeva II; Abakumova TV; Dolgova DR; Gening TP; Pirmamedova SS; Myasnikova DF; Gening SO
Anticancer Agents Med Chem; 2017; 17(9):1251-1255. PubMed ID: 28044937
[TBL] [Abstract][Full Text] [Related]
2. Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
Sokolenko AP; Savonevich EL; Ivantsov AO; Raskin GA; Kuligina ES; Gorodnova TV; Preobrazhenskaya EV; Kleshchov MA; Tiurin VI; Mukhina MS; Kotiv KB; Shulga AV; Kuznetsov SG; Berlev IV; Imyanitov EN
Cancer Lett; 2017 Jul; 397():127-132. PubMed ID: 28377179
[TBL] [Abstract][Full Text] [Related]
3. Cytokine gene polymorphisms in Egyptian cases with brain tumors.
Settin A; Ali N; Salem FK
Egypt J Immunol; 2008; 15(2):15-23. PubMed ID: 20306684
[TBL] [Abstract][Full Text] [Related]
4. The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yildirim Y; Ertas IE; Dogan A; Gultekin OE; Gultekin E
J Surg Oncol; 2012 Feb; 105(2):200-5. PubMed ID: 21815151
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor-α and interleukin-1β gene polymorphisms and risk of brain abscess in North Indian population.
Mishra P; Prasad KN; Singh K; Bajpai A; Sahu RN; Ojha BK
Cytokine; 2015 Sep; 75(1):159-64. PubMed ID: 26187330
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.
Loizzi V; Leone L; Camporeale A; Resta L; Selvaggi L; Cicinelli E; Cormio G
Oncology; 2016; 91(4):211-216. PubMed ID: 27487241
[TBL] [Abstract][Full Text] [Related]
7. Cytokine gene polymorphisms in hemodialysis patients: association with comorbidity, functionality, and serum albumin.
Balakrishnan VS; Guo D; Rao M; Jaber BL; Tighiouart H; Freeman RL; Huang C; King AJ; Pereira BJ;
Kidney Int; 2004 Apr; 65(4):1449-60. PubMed ID: 15086488
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.
Petrillo M; Paris I; Vizzielli G; Amadio G; Cosentino F; Salutari V; Scambia G; Fagotti A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S952-8. PubMed ID: 26036187
[TBL] [Abstract][Full Text] [Related]
9. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
[TBL] [Abstract][Full Text] [Related]
10. An association study of inflammatory cytokine gene polymorphisms in Fabry disease.
Safyan R; Whybra C; Beck M; Elstein D; Altarescu G
Eur Cytokine Netw; 2006 Dec; 17(4):271-5. PubMed ID: 17353161
[TBL] [Abstract][Full Text] [Related]
11. Role of neoadjuvant chemotherapy in the management of advanced ovarian yolk sac tumor.
Lu Y; Yang J; Cao D; Huang H; Wu M; You Y; Chen J; Lang J; Shen K
Gynecol Oncol; 2014 Jul; 134(1):78-83. PubMed ID: 24582864
[TBL] [Abstract][Full Text] [Related]
12. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer.
Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Gynecol Oncol; 2010 Apr; 117(1):109-16. PubMed ID: 20056267
[TBL] [Abstract][Full Text] [Related]
13. Impact of interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphism on IgA nephropathy.
Shu KH; Lee SH; Cheng CH; Wu MJ; Lian JD
Kidney Int; 2000 Aug; 58(2):783-9. PubMed ID: 10916103
[TBL] [Abstract][Full Text] [Related]
14. Evidence against a role for polymorphisms at tumor necrosis factor, interleukin-1 and interleukin-1 receptor antagonist gene loci in the regulation of disease severity in acute pancreatitis.
Powell JJ; Fearon KC; Siriwardena AK; Ross JA
Surgery; 2001 May; 129(5):633-40. PubMed ID: 11331456
[TBL] [Abstract][Full Text] [Related]
15. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
[TBL] [Abstract][Full Text] [Related]
16. [The vascular endothelial growth factor in patients with advanced ovarian cancer on the background of chemotherapy according to the AP scheme.].
Abakumova TV; Gening SO; Dolgova DR; Gening TP; Antoneeva II; Poludnyakova LV; Kuznetsova TI; Dergunova YA; Panchenko EG
Klin Lab Diagn; 2018; 63(9):543-548. PubMed ID: 30735319
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms in cytokine genes influence long-term survival differently in elderly male and female patients.
Cederholm T; Persson M; Andersson P; Stenvinkel P; Nordfors L; Madden J; Vedin I; Wretlind B; Grimble RF; Palmblad J
J Intern Med; 2007 Aug; 262(2):215-23. PubMed ID: 17645589
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery.
Ghaemmaghami F; Karimi-Zarchi M; Modares-Gilani M; Mousavi A; Behtash N
Asian Pac J Cancer Prev; 2008; 9(4):719-24. PubMed ID: 19256766
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.
Tecza K; Pamula-Pilat J; Kolosza Z; Radlak N; Grzybowska E
J Exp Clin Cancer Res; 2015 Jan; 34(1):2. PubMed ID: 25591549
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer.
Bushley AW; Ferrell R; McDuffie K; Terada KY; Carney ME; Thompson PJ; Wilkens LR; Tung KH; Ness RB; Goodman MT
Gynecol Oncol; 2004 Dec; 95(3):672-9. PubMed ID: 15581980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
